AP-325

DRUG2 trials

Sponsors

Algiax Pharmaceuticals GmbH, The Deutsche Diabetes Forschungsgesellschaft e.V.

Conditions

Peripheral Post-surgical Neuropathic PainType2 Diabetes

Phase 2

AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain

CompletedNCT04429919

Algiax Pharmaceuticals GmbHPeripheral Post-surgical Neuropathic Pain

Start: 2020-06-22End: 2024-10-04Updated: 2024-10-16

Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes

CompletedNCT05160272

The Deutsche Diabetes Forschungsgesellschaft e.V.Type2 Diabetes

Start: 2022-01-07End: 2024-12-17Updated: 2025-01-10